NMES, Exercise, and Glycemic Control in Older Adults With Type 2 Diabetes (NCT06856720) | Clinical Trial Compass
By InvitationNot Applicable
NMES, Exercise, and Glycemic Control in Older Adults With Type 2 Diabetes
Portugal75 participantsStarted 2025-10-27
Plain-language summary
Adults aged 60 years and older with type 2 diabetes living in nursing homes may experience difficulty participating in conventional exercise programs because of frailty, mobility limitations, or chronic health conditions. This randomized controlled trial compares three 12-week non-pharmacological interventions for glycemic management: neuromuscular electrical stimulation (NMES), supervised combined aerobic and resistance exercise, and a structured health literacy intervention. Participants will be randomly assigned to one of the three groups. The primary outcome is weekly mean fasting capillary glucose. Secondary outcomes include health-related quality of life, treatment satisfaction, adherence, and safety. The study aims to identify feasible and clinically relevant strategies for improving diabetes management in institutionalized older adults.
Who can participate
Age range
60 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Confirmed diagnosis of type 2 diabetes mellitus.
* Age 60 years or older.
* Resident in a nursing home or similar long-term care facility in Portugal.
* Able to understand study procedures and provide informed consent.
* Stable antidiabetic medication regimen for at least 12 weeks before enrollment.
Exclusion Criteria:
* Severe cognitive impairment or inability to provide informed consent.
* Acute or unstable medical condition making participation unsafe.
* Contraindications to moderate-intensity exercise.
* Implanted electronic devices (e.g., pacemaker, implantable cardioverter-defibrillator).
* Skin lesions or dermatological conditions preventing safe electrode placement.
* Any condition judged by the clinical team to preclude safe participation.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Weekly Mean Fasting Capillary Glucose
Timeframe: Baseline, weekly during the 12-week intervention period, and at 30-, 60-, and 90-day follow-up